Article in Immunological reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
2 authors.
Wilson W WongBiomedical Engineering and Biological Design Center, Boston University, Boston, Massachusetts, USA.ORCID 0000-0001-8394-889X
Wendell A LimCellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California, USA.
Funding
User-control and safetyU54CA244438 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2019 to 2022
$7.8M
Synthetic toolkit for precision gene expression control and signal processing in mammalian cellsR01EB029483 · NIBIB · HARVARD UNIVERSITY · PI Ahmad Samir Khalil · 2020 to 2026
$5.0M
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligandsR01DK132576 · NIDDK · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI BIRNBAUM, MICHAEL, CETRULO, CURTIS LISANTE · 2022 to 2025
$2.9M
Synthetic circuits that drive infiltration of therapeutic T cells into immunologically cold tumorsU01CA265697 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EL-SAMAD, HANA, LIM, WENDELL A · 2021 to 2025
$2.9M
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cellsR01CA249018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WENDELL A LIM · 2021 to 2026
$2.8M
Precise tumor targeting with logic CAR circuitsU01CA265713 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2021 to 2025
$2.5M
Ameliorating off-target toxicities of CAR T cells by engineering NOT gatesR01CA258789 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WENDELL A LIM · 2022 to 2026
$2.2M
Multiplexed and Logical Control of the Mammalian Transcriptome Using Cas13R01EB031904 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · 2021 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Golden age of immunoengineering. · full record | OpenQuestion